Going for diagnostic clout

The planned merger between Shield Diagnostics Group plc (LSE:SDG) and Axis Biochemicals AS (OSE:AXI) will create a heart disease testing company valued at about £160 million ($264 million) with enhanced clout when it comes to dealing with multinational diagnostics distributors.

While both companies could have continued on their

Read the full 472 word article

How to gain access

Continue reading with a
two-week free trial.